Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
Journal: The Journal of clinical and aesthetic dermatology
Published: December 19, 2025
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.
Journal: Advances in therapy
Published: December 18, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 19, 2024
Predatory Conferences and Journals in Dermatology Are Black Widow Parties.
Journal: Skinmed
Published: October 21, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: June 24, 2024
Management of scrotal pruritus with topical roflumilast 0.3% once daily treatment.
Journal: JAAD case reports
Published: April 05, 2024
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
Journal: The British journal of dermatology
Published: February 23, 2024
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Journal: Advances in therapy
Published: December 18, 2023
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
Journal: Journal of the American Academy of Dermatology
Published: December 01, 2023
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.
Journal: Journal of the American Academy of Dermatology
Published: May 25, 2023
Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
Journal: Journal of the American Academy of Dermatology
Published: May 19, 2023
Last Updated: 09/26/2026